- Includes Surgeon Panel, Strategic Updates, and Product Showcase -
- St. Regis Hotel, New York, 7:30 to 10:30 a.m. ET -
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA),
a medical device company focused on developing products for minimally
disruptive surgical treatments for the spine, announced today that it will
host a meeting for investors and analysts at the St. Regis Hotel, 2 East 55th
St., New York, NY on Tuesday, May 12, 2009 from 7:30 to 10:30 a.m. ET.
The agenda will include key updates from management, surgeon panel
presentations, audience Q&A with both management and surgeons, and hands-on
product demonstrations. Alex Lukianov, Chairman and Chief Executive Officer,
will open the meeting with a company update and then moderate a surgeon panel
with presentations and forum discussion on the following topics:
-- The economy's impact on a spine surgeon's practice and future outlook
-- Broad application of XLIF(R) to address increasing number of
indications
-- Advantages of XLIF and the lateral approach vs traditional surgery,
including physician insight into patient and economic benefits
-- Outcome comparison of XLIF enabled with NeuroVision(R) vs other
lateral techniques
-- Surgeon perspective on reimbursement environment for spine surgery
-- Experience with recent product additions in biologics and cervical
motion preservation
The surgeon panel will be followed by a product strategy overview and
demonstration by NuVasive management including updates on NuVasive's
Osteocel(R) Plus biologic and the recent acquisition of Cervitech(R) Inc.,
with its investigational PCM(R) cervical disc system. Various product booths
will be available for attendees to experience a hands-on demonstration with
the unique opportunity to speak with both NuVasive management and presenting
surgeons.
NuVasive is honored to have the participation of the following leading
spine surgeons:
-- Dr. Christopher R. Brown, Duke University Medical Center
-- Dr. Andrew Cappuccino, Buffalo Spine Surgery
-- Dr. Eric Elowitz, NYC Neurosurgery
-- Dr. James Hale, Eastern Orthopedic Associates
-- Dr. Robert Isaacs, Duke University Medical Center
-- Dr. W. Blake Rodgers, Spine Midwest, Inc.
-- Dr. William Smith, Western Regional Center for Brain & Spine Surgery
Several members of NuVasive executive management will be in attendance
including:
-- Alex Lukianov, Chairman and Chief Executive Officer
-- Keith Valentine, President and Chief Operating Officer
-- Kevin O'Boyle, Executive Vice President and Chief Financial Officer
A live webcast of the meeting will be available online from the investor
relations page of the Company's corporate website at www.nuvasive.com. After
the live webcast, the presentation will remain available on the website for 30
days.
About NuVasive
NuVasive is a medical device company focused on the design, development,
and marketing of products for the surgical treatment of spine disorders. The
Company's product portfolio is focused primarily on the $4.6 billion U.S.
spine implant market. Additionally, the Company has expanded into the $1.5
billion global biologics market, the $1.5 billion international market, and is
developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines four categories of
products that collectively minimize soft tissue disruption during spine
surgery with maximum visualization and safe, easy reproducibility for the
surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS significantly
reduces surgery time and returns patients to activities of daily living much
faster than conventional approaches. Having redefined spine surgery with the
MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or
XLIF(R), NuVasive has built an entire spine franchise. With nearly 50
products today spanning lumbar, thoracic and cervical applications, the
Company will continue to expand and evolve its offering predicated on its R&D
focus and dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which, if they do
not materialize or prove correct, could cause NuVasive's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties that could
cause actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or clearance
for NuVasive's products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require significant
changes to NuVasive's products or clinical studies; the risk that products may
not perform as intended and may therefore not achieve commercial success; the
risk that competitors may develop superior products or may have a greater
market position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasive's
products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's public filings
with the Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking statement to
reflect events or circumstances arising after the date on which it was made.
Contact: Investors:
Kevin C. O'BoylePatrick F. Williams
EVP & Chief Financial Officer Vice President, Finance & Investor
NuVasive, Inc. Relations
858-909-1998 NuVasive, Inc.investorrelations@nuvasive.com 858-638-5511
investorrelations@nuvasive.com
Media:
Jason RandoThe Ruth Group
646-536-7025
jrando@theruthgroup.com
SOURCE NuVasive, Inc.
05/06/2009
CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer,
+1-858-909-1998, or Investors, Patrick F. Williams, Vice President, Finance &
Investor Relations, +1-858-638-5511, both of NuVasive, Inc.,
investorrelations@nuvasive.com; or Media, Jason Rando, The Ruth Group,
+1-646-536-7025, jrando@theruthgroup.com
Web Site: http://www.nuvasive.com